Fistula News and Research

RSS

A Fistula is an abnormal opening or passage between two organs or between an organ and the surface of the body. Fistulas may be caused by injury, infection, or inflammation, or may be created during surgery.

FDA grants approval for new biosimilar to treat multiple types of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

14 Sep 2017

MSC transplantation can be safe, effective approach to treat Crohn's disease-related fistula

A growing body of clinical evidence shows that transplantation of a patient's own mesenchymal stem cells (MSCs) to achieve a cure and prevent recurrent of Crohn's disease-related fistula can be a safe and effective addition to surgery.

14 Sep 2017

Catheter use during hemodialysis linked to increased rates of bloodstream infections

Using catheters to access the blood during hemodialysis continues to be linked with increased rates of bloodstream infections, according to a recent analysis of data from US dialysis facilities. The findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology.

30 Jun 2017

Berlin meeting of colorectal specialists to drive best practice and innovation

It is less than five months to go until the 2017 ESCP Meeting, which is taking place in Berlin between 20 and 21 September. The meeting, hosted by the European Society of Coloproctology, brings together global experts to drive innovation and best practice in the field and will feature the latest coloproctological research.

8 Jun 2017

FDA approves use of new Flourish device to treat infants born with esophageal atresia

The U.S. Food and Drug Administration today authorized use of the Flourish Pediatric Esophageal Atresia Anastomosis, a first-of-its-kind medical device to treat infants up to one year old for a birth defect that causes a gap in their esophagus, called esophageal atresia.

12 May 2017

Stivarga receives expanded FDA approval for treatment of liver cancer

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.

28 Apr 2017

Report reveals hospitalization, mortality rates for kidney disease patients continue to decrease in the U.S.

According to an annual data report from the United States Renal Data System, hospitalization and mortality rates for patients with chronic kidney disease continue to decline in the U.S.

2 Dec 2016

Esperite's business unit develops therapy for Crohn's disease perianal fistulas

Esperite's business unit The Cell Factory in collaboration with Women's and Children's Health Department of the University of Padua and the Padua University Hospital are developing therapies for inflammatory bowel disease (IBD) using extracellular vesicles (EVs).

21 Oct 2016

New study questions longstanding belief related to hemodialysis patients treated with catheters

The findings of a new study call into question the longstanding belief that the higher risk of premature death seen in hemodialysis patients who are treated with catheters is due to an elevated risk of complications.

7 Oct 2016

Regenerative medicine shows promise for bronchopleural fistulas

When current treatment isn't enough, patients at Mayo Clinic often are among the first to benefit from innovative therapies, new techniques and technologies. For the first time in human application, Mayo Clinic researchers successfully closed an open wound on the upper chest caused by postoperative complications of lung removal.

25 Jun 2016

FDA approves novel stomach-draining device to treat obesity

The U.S. Food and Drug Administration today approved a new obesity treatment device that uses a surgically-placed tube to drain a portion of the stomach contents after every meal.

15 Jun 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Excess activation of LOX may play causative role in progression of cardiac failure

Heart failure is a progressive condition, where structural and functional alterations of the ventricle limit the ability of the heart to either fill or eject blood. There are approximately 550,000 new cases of heart failure each year with a prevalence of nearly 5 million; most patients die within five years of diagnosis.

2 Apr 2016

TVA Medical announces results from multicenter clinical study of everlinQ endoAVF System

TVA Medical, Inc., announced clinical trial results from a prospective, multicenter clinical study evaluating the everlinQ endoAVF System. This innovative medical technology creates hemodialysis access using vascular sites not traditionally used by surgeons for people with end-stage kidney disease (ESKD).

21 Nov 2015

Nurse-trainer uses new approach to teach correct combination of HIV drugs to Angola's nurses

Nurse-trainer Helena Cumbelembe Inacio was struggling to teach nurses at the health center here the correct combination of medicines to prevent pregnant women with HIV from passing the infection to their children.

11 Sep 2015

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Platform therapeutic company Symic Biomedical, Inc. announced today that it has received a $1.5M Phase II SBIR grant from the National Institutes of Health to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis.

27 Aug 2015

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).

20 Aug 2015

Uninterrupted NOAC treatment during catheter ablation of atrial fibrillation is safe, shows research

Uninterrupted treatment with novel oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) is safe, reveals research presented today at EHRA EUROPACE - CARDIOSTIM 2015 by Dr Carsten Wunderlich, senior consultant in the Department of Invasive Electrophysiology, Heart Centre Dresden, Germany.

25 Jun 2015

Study reveals how geography affects the survival of people with end-stage kidney disease

The notion that geography often shapes economic and political destiny has long informed the work of economists and political scholars. Now a study led by medical scientists at Johns Hopkins reveals how geography also appears to affect the very survival of people with end-stage kidney disease in need of dialysis.

24 Jun 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015